trending Market Intelligence /marketintelligence/en/news-insights/trending/9ahn4x6tnjczkafwfmgp8q2 content esgSubNav
In This List

INSYS Therapeutics' painkiller spray rejected by US FDA over safety concerns

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


INSYS Therapeutics' painkiller spray rejected by US FDA over safety concerns

INSYS Therapeutics Inc. said the U.S. Food and Drug Administration rejected its application to market a buprenorphine spray as a treatment for moderate-to-severe acute pain.

The company received a complete response letter from the regulator flagging potential safety concerns for the spray, which is applied under the tongue.

The Chandler, Ariz.-based company added that the letter indicated that the buprenorphine spray was statistically significantly different than placebo in providing pain relief.

The FDA's decision comes after the agency's expert panel voted in May not to recommend the approval of the therapy.

Steve Sherman, INSYS Therapeutics' senior vice president of regulatory affairs, said the company is in the process of assessing its next steps.